Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer (terminated evaluation). NICE technology appraisal guidance 1198
National Institute for Health and Care Excellence (NICE)
Record ID 32018016109
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/terminated/ta1198
Year Published:
2026
URL for published report:
https://www.nice.org.uk/guidance/terminated/ta1198
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Small Cell Lung Carcinoma
- Lung Neoplasms
- Antineoplastic Combined Chemotherapy Protocols
- Antibodies, Monoclonal, Humanized
- Immune Checkpoint Inhibitors
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
3rd floor, 3 Piccadilly Place, Manchester, M1 3BN
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.